In silico transcriptomics identifies FDA-approved drugs and biological pathways for protection against cisplatin-induced hearing loss
Pezhman Salehi, Marisa Zallocchi, Sarath Vijayakumar, Madeleine E. Urbanek, Kimberlee P. Giffen, Yuju Li, Santanu Hati, Jian Zuo
The paper uses in silico transcriptomics to identify FDA-approved drugs and pathways that protect against cisplatin-induced hearing loss, validating niclosamide as a potential otoprotectant.
bioRxiv · Jan 26, 2022 · PreprintNeuroscience